1. Introduction {#sec1}
===============

Since the first heart valve bank (HVB) started in New Zealand in 1962, the recovery, processing, and storage techniques have been constantly evolving to improve the quality and safety of cardiovascular allografts for clinical implantation. During the initial era of allograft usage, fresh aseptically recovered allografts were implanted within hours or days of recovery. This was followed by aggressive decontamination methods, such as gamma-irradiation and chemical sterilisation using formaldehyde, glutaraldehyde, beta-propiolactone, and ethylene oxide. Coupled with harsh preservation techniques of freeze-drying and flash-freezing in liquid nitrogen, these "sterilised" tissues rapidly failed *in situ* due to high incidence of leaflet degeneration, cusp rupture, and/or loss of durability and hemodynamic function. For these reasons, allograft use was discontinued until newer preservation methods were developed. Eventually, "sterilised" tissues were replaced by aseptically recovered ones treated with antibiotics and stored in culture media at 4°C for up to 6 weeks. These milder techniques improved valve durability and, ultimately, patient outcome. Today, the majority of HVBs worldwide use aseptic retrieval of donor heart valves followed by low-dose antibiotic decontamination, cryopreservation, and storage at ultralow temperature until the valves are required for implantation \[[@B1]--[@B3]\].

Regulatory bodies throughout the world promote global harmonisation of manufacturing procedures as a mean to standardise product quality and safety and to simplify the exchange of "like" products between jurisdictions. Although standardisation is a rational approach for many processes, genuine differences and restrictions in manufacturing circumstances, such as differences in endemic microbial contaminants and patented processes, may limit the extent to which standardisation can be achieved. In addition, as changes to critical processes require validation, which can be both costly and time consuming, any proposed change must be justified in terms of risks and cost benefits for the HVB and the recipient. As a result, even though tissue banking associations and regulatory bodies governing HVBs worldwide promote similar quality and safety standards for allografts, differences in processing procedures used to achieve these outcomes continue to exist. Essentially, all HVBs follow standards developed by their regional tissue banking associations, which are designed to meet regulatory requirements of their jurisdiction. For instance, in North America, most HVBs follow the standards of the American Association of Tissue Banks (AATB). The European Association of Tissue Banks (EATB), British Association for Tissue Banking (BATB), Associación Español de Bancos de Tejidos (AEBT), and the Spanish Association of Tissue Banks (SATB) have published tissue banking standards for European banks \[[@B4]\]. In Australia, the Australasian Tissue and Biotherapeutics Forum (ATBF) has developed standards that align with the Therapeutic Goods Administration\'s (TGA) new Biologicals Regulatory Framework. In Asia, the Asia-Pacific Association of Surgical Tissue Banking (APASTB) was formed to encourage tissue-focused research and to promote scientific and social interaction among its members. In all cases, the standards developed by these tissue-banking associations stipulate donor suitability criteria, aseptic processing procedures, and controlled storage requirements of transplantable human tissues, with the common objective of assuring that recipients receive disease- and contaminant-free allografts that fulfil optimum clinical performance \[[@B2]\].

In February 2011, a survey of 24 HVBs in North America, Europe, Australasia, and South Africa was initiated by coauthor Linda Manning. The survey was designed to collate data on heart valve processing procedures and outcomes to inform HVBs and their regulatory bodies on the similarities and differences in heart valve manufacturing activities worldwide. This information was subsequently compiled and presented at the ATBF\'s 12th Annual Scientific and Business meeting held in Melbourne, Australia, in May 2011 and the AATB\'s 35th Annual Meeting held in Arizona, USA, in September 2011. This paper reports the comprehensive data collected from individual HVBs as part of this survey.

2. Materials and Methods {#sec2}
========================

The original survey was distributed by electronic mail to 24 HVBs in North America, Europe, Australia, New Zealand, Asia, and South Africa. They were asked to provide information to the following questions, which addressed two aspects.Allograft processing and storage procedures:what processing media does your bank use?what antibiotic regimen does your bank use?what cryopreservation method does your bank use?did your bank conduct a formal validation on the media, antibiotics, and antibiotic incubation protocols that you use?what storage conditions and duration does your bank use for allografts meeting release criteria?Processing outcome of HVBs:how many donors and allografts does your bank process annually?what proportion of allografts meet release criteria?what are the most common reasons allografts fail to meet release criteria?what proportion of allografts released for clinical use is implanted?what are the primary reasons why released allografts are not implanted?

Data was collated from February to April 2011. In this report, the results were summarised and presented as returned, apart for editing for consistency of terminology. The individual HVBs had been deidentified. The Royal Perth Hospital\'s Cell and Tissue Therapies WA\'s Management Committee was consulted prior to implementation of study, and ethics approval was advised to be unnecessary, as the survey was a mere collation of information on the individual HVBs\' practices and outcomes, which did not involve the identification of patients.

3. Results {#sec3}
==========

3.1. Tissue Processing and Storage Procedures {#sec3.1}
---------------------------------------------

24 HVBs participated in this aspect of study. As presented in Tables [1](#tab1){ref-type="table"}, [2](#tab2){ref-type="table"}, and [3](#tab3){ref-type="table"}, both similarities and differences in heart valve processing and storage procedures were identified in the survey. Isotonic solutions or cell culture media were used for valve retrieval, antibiotic decontamination, and cryopreservation. Eleven HVBs (46%) used Medium 199 (M199), and five (21%) used Roswell Park Memorial Institute Media 1640 (RPMI-1640), while the remainder used Dulbecco\'s Modified Eagle\'s Medium (DMEM), sodium chloride (normal saline), Hanks Balanced Salt Solution (HBSS), or Ringer\'s lactate ([Table 5](#tab5){ref-type="table"}). Twelve of the 18 HVBs (66%) reported using 9%--11% DMSO as cryoprotectant, with the rest using varying concentrations of DMSO (7.5%--20%) with or without foetal bovine serum or human albumin. In all cases, the media/solutions were purchased as sterile reagents from approved suppliers.

Antibiotic decontamination regimens were found to be exceptionally diverse, both in the antibiotic combinations used (Tables [1](#tab1){ref-type="table"}--[3](#tab3){ref-type="table"}) and their concentrations ([Table 4](#tab4){ref-type="table"}). The most commonly used antibiotics were vancomycin (15 banks) and gentamicin (10 banks). Seven HVBs also included antifungal drugs in their antibiotic cocktail-five used amphotericin B, one used fluconazole, and another used fungoral.

Most of the European HVBs and half of the North American HVBs surveyed incubated allografts at 4°C for 24 hours. In contrast, five of the seven HVBs surveyed from Australasia and South Africa decontaminated their valves at physiological temperature of 37°C for ≤12 hours. Overall, 16 HVBs (67%) conducted bioburden reduction at cold temperatures (1°C--10°C), with seven HVBs (29%) incubating at 33°C--38°C. Duration of bioburden reduction step varied from 6 to 48 hours, with a majority of the HVBs incubating for 18--26 hours at cold temperatures (12 of 16 banks = 75%). Those using physiological temperatures (33°C--38°C) incubated for either 18--26 hours (3 of 7 banks = 43%) or 6--12 hours (4 of 7 banks = 57%). Two HVBs conducted bioburden reduction at ambient temperature for 24 hours. One HVB decontaminated allografts at either 37°C for 6--8 hours or 4°C for 18--24 hours ([Table 6](#tab6){ref-type="table"}).

92% of HVBs (22 of 24 banks) used controlled rate freezing to cryopreserve cardiovascular tissues, with the remaining two HVBs using manual freezing in liquid nitrogen vapour phase. All HVBs stored processed allografts at ultralow temperatures (\<−135°C) or in liquid nitrogen vapour phase. Storage duration ranged from 2 to 15 years, with the majority of HVBs (16 of 23 banks = 70%) storing released homografts for five years.

The procedures used for processing, bioburden reduction, cryopreservation, and storage had been validated by all responding HVBs.

3.2. HVBs\' Processing Activities and Outcomes {#sec3.2}
----------------------------------------------

23 HVBs participated in this aspect of study. A summary of the heart valve processing activities and outcomes is presented in Tables [7](#tab7){ref-type="table"}, [8](#tab8){ref-type="table"}, and [9](#tab9){ref-type="table"}. The annual number of donors and allografts processed by the different HVBs varied extensively both between and within jurisdictions. Donor numbers ranged from 4 to over 3700, with 8 to 8500 allografts processed annually. Many HVBs in Europe, North America, Australasia, and South Africa have less than 50 donors annually. In contrast, there are two, very large HVBs in North America, which processe allografts from more than 1000 donors each year ([Table 10](#tab10){ref-type="table"}).

On average, 70% of the processed allografts (range = 39%--90%; mean = 69%) met the HVBs\' release criteria. Twenty-one HVBs (21 of 23 banks = 91%) reported positive microbiology results as a primary reason for allografts failing to meet release criteria. Ten (10 of 23 banks = 43%) listed abnormal morphology of tissues, which is defined as presence of calcification, excessive atheroma (particularly in aortic valves), excessive fenestrations, fibrosis, dilatation, and sinus aneurysm, as a reason for product failure. Positive serology results of donor, valve incompetency during testing, technical issues, quality, and donor related findings (e.g., medical contraindication) were also cited as reasons for product failure. One large North American HVB deferred further processing of donor tissues based on low clinical demand of a certain valve type (i.e., aortic valve) and valve sizes ([Table 11](#tab11){ref-type="table"}).

On average, 85% of allografts meeting release criteria (range = 50%--100%) were implanted. Uncontrollable factors such as low demand for aortic valves, nonvalve allografts, and certain valve sizes were cited as the primary reason for released products not being implanted by 17 HVBs (17 of 23 banks = 74%). The majority of these valves were discarded due to reaching maximum storage duration. Clinical decision during surgery was also cited as a reason why valves were not implanted. Other factors, which could be monitored and potentially improved upon, include perioperative incidents, such as incorrect valve size delivered to implant hospitals, damage during thawing, and intraoperative contamination of allograft. Four HVBs cited these factors as reasons that prevented implantation of released allografts (4 of 23 banks = 17%) ([Table 11](#tab11){ref-type="table"}).

4. Discussion {#sec4}
=============

Based on the information published in 2004, there are 85 HVBs worldwide, with the majority located in Europe, Canada, USA, and Australia. There are only three HVBs in Asia \[[@B5]\]. From the responses collated from 24 of these HVBs located in various jurisdictions, it is obvious that global harmonisation of heart valve manufacturing procedures has not been achieved. This is not surprising, as each country has different microbial, environmental, regulatory, and logistical challenges to overcome. Despite so, the more routine processing aspects appeared to be relatively standardised. These included (1) the use of sterile culture media for all processing steps, with the majority of banks using either M199 or RPMI-1640, (2) the use of DMSO as a cryoprotectant, with 72% of the banks utilising this reagent at a concentration of 9%--11%, (3) bioburden reduction by antibiotic disinfection, (4) controlled rate freezing for cryopreservation of allografts, and (5) storage of allografts at ultralow temperatures of below −135°C or in liquid nitrogen vapour phase.

However, in terms of procedural details, numerous differences were also identified. They included (1) type of sterile culture media used for processing, (2) antibiotics combination, (3) temperature and duration used for bioburden reduction, (4) concentration of DMSO used for cryopreservation, and (5) storage duration for released homografts. These differences in processes, which in some cases had been patented by the individual HVBs, had been validated.

Antibiotic cocktails used for bioburden reduction were diverse in terms of the number, combination, and concentrations of antibiotics used. Vancomycin and gentamicin were the most commonly used antibiotics, with approximately 80% of HVBs using one or both of these antibiotics. It is noteworthy that some HVBs were found to prefer first-generation antibiotics, such as penicillin and streptomycin, whereas others chose to use newer, broader spectrum antimicrobials, such as vancomycin and gentamicin. The decision to retain the antibiotics cocktail is probably because the effectiveness of these antibiotics had been validated by the HVBs and no protocol change was warranted. However, as continuous improvement in tissue manufacturing is encouraged, it is important that HVBs routinely review their antibiotic regimens, concentrations, and incubation conditions, to ensure optimal product quality, function, and safety.

The incubation temperature used for bioburden reduction also varied. Interestingly, there appeared to be a regional preference for different tissue incubation temperatures. This trend had previously been reported by Parker. In his study, he found that most tissue banks in Europe and North America treated allografts with antibiotics at 4°C, whereas banks in Australia conducted antibiotics decontamination step at 37°C \[[@B6]\]. Our survey confirmed these findings, with most banks in Europe and North America incubating recovered donor tissues at 1°C--10°C for 18--24 hours and the majority of banks in Australasia incubating at 35°C--37°C for 6--12 hours. One Australasian HVB had validated both temperatures (4°C and 37°C) for varying durations (18--24 hours and 6--8 hours, resp.) to ensure that processing could be completed within the required time frame.

Differences in duration and temperature of bioburden reduction step, as well as the combination and concentration of antibiotics used by individual HVBs, can be attributed to a number of factors. Firstly, the fact that each procedure had been validated, in some cases patented, and shown to be effective in removing detectable microbial contamination from the allografts, justifies the retention of both antibiotic cocktail and incubation procedure for each HVB. In addition, differences in endemic microorganisms sensitive to different antibiotics are also valid reasons for maintaining these procedural differences between different HVBs.

Although different antibiotics function optimally within specific temperature ranges and possess varying degrees of stability, maximal antibiotic activity is generally achieved at a physiological temperature of 37°C, when most micro-organisms are actively replicating \[[@B7], [@B8]\]. A comprehensive study conducted in 2010 by Germain et al. demonstrated that exposure to antibiotics at 37°C resulted in a rapid decrease in the number of colony-forming units of 12 bacterial strains \[[@B8]\]. In addition, the results of a recent study by Fan et al. suggested that the lower decontamination success rate observed when bioburden reduction step was conducted at 4°C was because the micro-organisms were not actively replicating at this temperature. This was particularly relevant for slow-growing organisms, such as the common skin contaminant, *Propionibacterium acnes*\[[@B9]\]. However, it is recognised that disinfecting tissues at this lower temperature has the advantages of reducing bacterial proliferation, as well as preventing warm ischemia damage to the tissue \[[@B9], [@B10]\]. To minimise potential ischemic damage, most HVBs that incubated allografts at 37°C used an incubation time of ≤12 hours \[[@B7]\].

It is noteworthy that the antifungal drug, amphotericin B, was included in the antibiotic cocktail of some HVBs, when its usage had been discontinued in others \[[@B7], [@B11]\]. Deleterious effects of amphotericin B on human tissue viability and cell damage were reported by various studies \[[@B12], [@B13]\]. However, the necessity to preserve cell viability for optimal graft function remained controversial. There is clinical evidence that viable valves at the time of cryopreservation had a lower level of structural deterioration than that of nonviable valves. Such valves were more likely to retain thicker leaflets and fewer perforations, as compared with nonviable valves \[[@B14]\]. Conversely, studies have reported the loss of cell viability after cryopreservation and thawing, suggesting that viable cells might not contribute to valve function and durability *in situ*\[[@B15]\]. It has even been suggested that the presence of viable cells in the graft may actually increase immunogenicity*in situ* \[[@B16], [@B17]\]. Nonetheless, the presence of viable cells precryopreservation is recognised as a useful indicator of optimal tissue preservation \[[@B14]\].

Despite the extensive variation in antibiotic regimens, reported decontamination success rates remain comparable at between 60% and 70% for different HVBs \[[@B9]\]. This confirmed the results of our survey where the mean proportion of allografts meeting clinical release criteria was found to be 69%. However, when comparing the proportion of valves meeting release criteria achieved by individual HVBs, the results were actually quite disparate (range = 39%--90%). This finding appeared to reflect the stage at which tissue exclusion criteria were applied. Some HVBs might have processed all donors\' tissues prior to application of tissue exclusion criteria, while others ensured that the criteria were met prior to processing. One large North American HVB chose not to process valves based on low clinical demand for the valve type (i.e., aortic valve) and/or size, which reduced the proportion of their products released for implant to only 39%.

Storage duration for released valves ranged from 2 to 15 years, with the majority of HVBs (\~70%) storing the allografts for 5 years. Some groups advocated that allografts should be stored for ≤5 years. However, this limit was based on convention rather than a validated study. Mirabet et al. concluded that any significant loss of cell viability in tissues stored in liquid nitrogen for ≤13 years was due to freezing and thawing protocols rather than the storage duration \[[@B18]\].

Almost all HVBs cited "positive microbiological culture of graft" as one of the primary reasons for allografts failing to meet release criteria. Several factors, such as the recovery site environment, sequence of tissue recovery, aseptic recovery and processing techniques, and suboptimal effectiveness of antibiotics used for decontamination, could contribute to this result. Fan et al. reported a significantly higher initial contamination rate of arterial tissues compared to heart tissues, which was ascribed to the less sterile state of the abdominal compartment where the arteries were recovered, especially if trauma was involved \[[@B9]\]. The Prince Charles Hospital also reported high contamination rates when they initiated valve retrieval from multiorgan donors. A review of procedures found contamination to be more common if previous retrieval teams had perforated the bowel or the heart had been removed with instruments used to retrieve other tissues. A higher incidence of contamination has also been reported for valves recovered in an open mortuary area due to the reduced air quality of the mortuary environment \[[@B7]\]. Given the numerous sources for potential contamination, effective aseptic practices at all stages of tissue recovery and processing are essential to minimise the risk of tissue contamination and loss of products.

Over the last thirty years, there has been a significant change in clinical demand for allografts from aortic valves to pulmonary valves. The reasons for this change include an increase in paediatric cardiac surgery, the adoption of the Ross procedure, and improved durability of aortic porcine valves \[[@B19], [@B20]\]. Various reports also associated the use of aortic valves with more rapid failure than pulmonary valves \[[@B21], [@B22]\]. The reduced clinical demand for aortic valves, along with low demand for certain valve sizes, were cited as the primary reasons why released valves were not implanted by the majority of HVBs. Together, these valves represented the majority of grafts discarded due to maximum storage duration attained. Other graft types, such as patches, face a similar challenge due to the ready availability of cost-effective animal-sourced patches.

There are several limitations to this study. Firstly, there were only 24 HVBs, which participated in this survey. This means that the processing practices and outcomes of many other HVBs remain unknown. Secondly, although all HVBs performed formal validation on major processes, the test methodologies used were different. Thirdly, there is a lack of patient-related parameters, which are more accurate measurements to the quality of final products and, ultimately, the success of transplanted allografts. Ideally, parameters such as early leaflet failure, iatrogenic infection, and other perioperative adverse events of patients, due to processing variables and thawing protocols, should be reviewed. While beyond the scope of this paper, a separate study should be performed to address these issues and potentially identify practical solutions.

Although the findings of this survey suggested that procedures currently in use by the individual HVBs were validated, in consideration of the wide variation in percentage of allografts fulfilling release requirements (range = 39%--90%), some purportedly validated protocols may not be performing as optimally as others. This seems to present an opportunity for improvement in the heart valve banking industry. As underperforming protocols will incur substantial losses to HVBs, all efforts to improve HVBs\' processing activities and recipient outcomes should be encouraged. Although "global harmonisation" is a worthy goal, it is doubtful if this can be achieved in the heart valve banking industry for a number of reasons, which include patented processes, organisational restrictions, and environmental differences. However, regular reviews of important outcomes as cited in this paper and monitoring of adverse patient events should encourage comparison and improvements in the HVBs\' processes.

The authors are greatly appreciative of all the heart valve banks who participated in this survey and generously shared their own banks\' practices.

###### 

Summary of heart valve processing protocols used by HVBs in Europe.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bank number   Processing media                                                                               Antibiotic regimen                             Incubation protocol                       Cryopreservation method                                                                                                 Storage condition and duration
  ------------- ---------------------------------------------------------------------------------------------- ---------------------------------------------- ----------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------
  E1            Until 2004: M199\                                                                              Vancomycin: 500 ug/mL\                         Room temperature, 24 hours, in the dark   Controlled rate freezing                                                                                                Liquid nitrogen vapour phase: 5 years
                2004 onwards: RPMI-1640                                                                        Gentamycin: 50 ug/mL\                                                                                                                                                                                            
                                                                                                               Piperacillin: 500 ug/mL\                                                                                                                                                                                         
                                                                                                               Nystatin: 2500 U/mL                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                

  E2            RPMI-1640 with glutamine\                                                                      Cefoxitin: 240 ug/mL\                          4°C, 24 hours                             Controlled rate freezing from +10°C to −110°C                                                                           Liquid nitrogen vapour phase: 5 years
                Addition of 20% human albumin and DMSO for cryopreservation and storage                        Lincomycin: 120 ug/mL\                                                                                                                                                                                           
                                                                                                               Colimycin: 100 ug/mL\                                                                                                                                                                                            
                                                                                                               Vancomycin: 50 ug/mL                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                

  E3            Transport solution: TRIS buffered isotonic saline\                                             Gentamicin: 4000 ug/mL\                        2--8°C, 18--24 hours                      Controlled rate freezing (at −1°C/min)                                                                                  −135°C: 10 years
                Antibiotics media: M199\                                                                       Imipenem: 200 ug/mL\                                                                                                                                                                                             
                Cryopreservation media: HBSS with 25 mM HEPES + 20% DMSO                                       Nystatin: 2500 U/mL\                                                                                                                                                                                             
                                                                                                               Polymyxin B: 200 ug/mL\                                                                                                                                                                                          
                                                                                                               Vancomycin: 50 ug/mL                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                

  E4            Cryopreservation media: HBSS with 25 mM HEPES + 10% DMSO                                       Vancomycin: 50 ug/mL\                          Room temperature (21°C), 24 hours         Controlled rate freezing                                                                                                Liquid nitrogen vapour phase: 10 years
                                                                                                               Gentamicin: 4000 ug/mL\                                                                                                                                                                                          
                                                                                                               Ciprofloxacin: 200 ug/mL\                                                                                                                                                                                        
                                                                                                               Amphotericin B: 50 ug/mL                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                

  E5            Antibiotics media: RPMI-1640\                                                                  Metronidazol: 50 ug/mL\                        4°C, 24 hours                             Controlled rate freezing                                                                                                Liquid nitrogen vapour phase: 15 years
                Cryopreservation media: RPMI-1640 + 10% DMSO                                                   Vancomycin: 50 ug/mL\                                                                                                                                                                                            
                                                                                                               Amikacin: 50 ug/mL\                                                                                                                                                                                              
                                                                                                               Amphotericin B: 5 ug/mL                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                

  E6            Cryopreservation media: 70% TC-199 + 10% DMSO + 20% human albumin                              Vancomycin: 50 ug/mL\                          4°C, 6--24 hours                          Controlled rate freezing (at −1°C/min)                                                                                  Liquid nitrogen vapour phase: 10 years
                                                                                                               Tobramycin: 50 ug/mL Cotrimoxazole: 50 ug/mL                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                

  E7            Cryopreservation media: M199 in the past, use sodium chloride solution + 10% DMSO at present   Fluconazole: 200 mg\                           4°C, 24 hours                             Liquid nitrogen vapour phase                                                                                            Liquid nitrogen vapour phase: 2 years
                                                                                                               Cefotaxime: 1 g                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                

  E8            Antibiotic media: 0.9% sodium chloride\                                                        Metronidazole: 20 ug/mL\                       4°C, at a minimum of 12 hours             Controlled rate freezing (down to −180°C)                                                                               Liquid nitrogen vapour phase: 5 years
                Cryopreservation media: RPMI-1640 + 10% cryoprotectant                                         Gentamicin: 20 ug/mL\                                                                                                                                                                                            
                                                                                                               Flucloxacillin: 20 ug/mL                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                

  E9            M199 with Hanks\' salts, L-glutamine, 25 mM HEPES                                              Lincomycin,\                                   4°C, 48 hours                             No response provided                                                                                                    Liquid nitrogen vapour phase: 5 years
                                                                                                               polymyxin B sulphate,\                                                                                                                                                                                           
                                                                                                               vancomycin                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                

  E10           M199\                                                                                          Amphotericin B: 250 ug/mL\                     4°C--8°C, 24 hours                        Controlled rate freezing                                                                                                Liquid nitrogen vapour phase: 10 years
                Antibiotics media: 200 mL of Earles salt in M199                                               Fungoral: 100 ug/mL\                                                                                                                                                                                             
                                                                                                               Colistin: 200 ug/mL\                                                                                                                                                                                             
                                                                                                               Vancocin: 500 ug/mL\                                                                                                                                                                                             
                                                                                                               Garamycin: 530 ug/mL                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                

  E11           Transport solution: Ringer\'s lactate or cardioplegia solution\                                Cefuroxime: 250 ug/mL\                         37°C, 18--24 hours                        Controlled rate freezing (from +4°C to −60°C at 1°C per min; then transfer to ultralow temperature freezer at −140°C)   Ultralow temperature (−140°C): 5 years or −80°C: for up to 6 months
                Antibiotic media: M199\                                                                        Gentamicin: 80 ug/mL\                                                                                                                                                                                            
                Cryopreservation media: M199 + Antibiotics + 12.5% DMSO                                        Ciprofloxacin: 200 ug/mL\                                                                                                                                                                                        
                                                                                                               Vancomycin: 500 ug/mL\                                                                                                                                                                                           
                                                                                                               Colistin: 1000 IU/mL\                                                                                                                                                                                            
                                                                                                               Amphotericin B: 20 ug/mL                                                                                                                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of heart valve processing protocols used by HVBs in North America.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bank number   Processing media                                                             Antibiotic regimen                                  Incubation protocol                                     Cryopreservation method    Storage condition and duration
  ------------- ---------------------------------------------------------------------------- --------------------------------------------------- ------------------------------------------------------- -------------------------- ----------------------------------------
  N1            Heart recovery, transport, and dissection solution: Ringer\'s lactate\       Vancomycin: 50 ug/mL\                               Until the 28th of June 2010: 1°C--10°C, 22--26 hours\   Controlled rate freezing   No response provided
                Antibiotics media: DMEM with Hepes\                                          Gentamicin: 80 ug/mL\                               Present: 33°C--38°C, 18--26 hours                                                  
                Cryopreservation media: DMEM + 7.5% DMSO                                     Cefoxitin: 240 ug/mL                                                                                                                   

                                                                                                                                                                                                                                    

  N2            Antibiotics media: RPMI-1640\                                                Cefoxitin,\                                         4°C, 24 hours                                           Controlled rate freezing   Liquid nitrogen vapour phase: 5 years
                Cryopreservation media: X-VIVO-10 + DMSO                                     colymycin-M,\                                                                                                                          
                                                                                             vancomycin,\                                                                                                                           
                                                                                             lincomycin                                                                                                                             

                                                                                                                                                                                                                                    

  N3            Transport and storage solution:\                                             Gentamicin: 80 mg/mL\                               4°C, 24 hours                                           Controlled rate freezing   Ultralow temperature (−140°C): 5 years
                Hanks solution\                                                              Cefazolin or Kefzol: 1 mg/mL                                                                                                           
                Dissection solution: saline\                                                                                                                                                                                        
                Cryopreservation media: 10% DMSO                                                                                                                                                                                    

                                                                                                                                                                                                                                    

  N4            Transport and processing solution: Ringer\'s lactate\                        Cefoxitin: 240 ug/mL\                               1°C--10°C, 22--26 hours                                 Controlled rate freezing   Liquid nitrogen vapour phase: 5 years
                Cryopreservation media: saline + RPMI-1640 + RPMI 1640 with 10% FBS + DMSO   Polymyxin B: 100 mg/mL\                                                                                                                
                                                                                             Vancomycin: 50 ug/mL\                                                                                                                  
                                                                                             Lincomycin: 120 ug/mL\                                                                                                                 
                                                                                             (soon to use gentamicin)                                                                                                               

                                                                                                                                                                                                                                    

  N5            DMEM\                                                                        Two-stage process:\                                 Warm solutions, \>24 hours                              Controlled rate freezing   Liquid nitrogen vapour phase: 5 years
                Cryopreservation media:\                                                     1st cocktail to achieve primary decontamination,\                                                                                      
                cardiac tissue---DMEM + DMSO + FBS\                                          2nd cocktail to support tissue                                                                                                         
                vascular tissue---DMEM + DMSO + chondroitin + FBS                                                                                                                                                                   

                                                                                                                                                                                                                                    

  N6            RPMI-1640                                                                    Vancomycin: 50 ug/mL\                               4°C, 24 ± 2 hours                                       Controlled rate freezing   Liquid nitrogen vapour phase: 5 years
                                                                                             Colymycin M: 75 mg/mL\                                                                                                                 
                                                                                             Cefoxitin: 100 mg/mL\                                                                                                                  
                                                                                             Lincomycin: 300 mg/mL                                                                                                                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of heart valve processing protocols used by HVBs in Australasia and South Africa.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bank number   Processing media                                            Antibiotic regimen            Incubation protocol                     Cryopreservation method                                                  Storage condition and duration
  ------------- ----------------------------------------------------------- ----------------------------- --------------------------------------- ------------------------------------------------------------------------ ------------------------------------------
  A1            Heart collection, transport, dissection solution:\          Amoxicillin: 20 ug/mL\        37°C, 6--8 hours or 4°C, 18--24 hours   Controlled rate freezing                                                 Liquid nitrogen vapour phase: 5 years
                Hartmann solution\                                          Gentamicin: 20 ug/mL                                                                                                                           
                Antibiotic media: M199\                                                                                                                                                                                    
                Cryopreservation media:\                                                                                                                                                                                   
                M199 + 10% DMSO                                                                                                                                                                                            

                                                                                                                                                                                                                           

  A2            Heart collection, transport, dissection solution:\          Penicillin: 50 IU/mL\         35°C, 6--8 hours                        Controlled rate freezing (back up: manual controlled rate freezing)      Liquid nitrogen vapour phase: 5 years
                saline or M199\                                             Streptomycin: 50 ug/mL                                                                                                                         
                Antibiotic media: M199\                                                                                                                                                                                    
                Cryopreservation media:\                                                                                                                                                                                   
                M199 + 10% DMSO                                                                                                                                                                                            

                                                                                                                                                                                                                           

  A3            Heart collection, transport, dissection solution:\          Penicillin: 50 IU/mL\         37°C, 6--12 hours                       Controlled rate freezing                                                 Liquid nitrogen vapour phase: 10 years
                DCD/multiorgan donors/live donors---saline\                 Streptomycin: 50 ug/mL                                                                                                                         
                Cadaveric---saline or M199 with antibiotics\                                                                                                                                                               
                Cryopreservation media:\                                                                                                                                                                                   
                M199 + 10% DMSO                                                                                                                                                                                            

                                                                                                                                                                                                                           

  A4            Heart collection, transport, dissection solution:\          Benzylpenicillin: 30 ug/mL\   37°C, 6 hours                           Controlled rate freezing                                                 Liquid nitrogen vapour phase: 5 years
                Hartmann solution\                                          Gentamicin: 18 ug/mL                                                                                                                           
                Antibiotic media: M199\                                                                                                                                                                                    
                Cryopreservation media:\                                                                                                                                                                                   
                M199 + 10% DMSO                                                                                                                                                                                            

                                                                                                                                                                                                                           

  A5            Heart collection, transport, dissection, rinse solution:\   Cefoxitin: 240 ug/mL\         First soak: 4°C, 24 hours;\             Freezing in liquid nitrogen vapour---no controlled rate equipment used   Liquid nitrogen vapour phase: 5 years
                HBSS (preferred) or saline\                                 Lincomycin: 120 ug/mL\        2nd soak: 4°C, 24 hours;\                                                                                        
                Antibiotic media: HBSS\                                     Polymyxin B: 100 ug/mL\       transfer to HBSS at 4°C until frozen                                                                             
                Cryopreservation media:\                                    Vancomycin: 50 ug/mL\                                                                                                                          
                Until Jan 2010---M199 + 10% DMSO\                           Amphotericin B: 25 ug/mL                                                                                                                       
                After Jan 2010---HBSS + 10% DMSO                                                                                                                                                                           

                                                                                                                                                                                                                           

  A6            Transport, dissection, incubation solution: M199\           Vancomycin: 50 ug/mL\         4°C, 24 hours                           Controlled rate freezing                                                 Liquid nitrogen vapour phase: 5 years
                Cryopreservation media:\                                    Amikacin: 100 ug/mL                                                                                                                            
                M199 + 100% DMSO diluted to 10%                                                                                                                                                                            

                                                                                                                                                                                                                           

  A7            M199\                                                       Mefoxin: 50 ug/mL\            4°C, 12--18 hours                       Controlled rate freezing                                                 Liquid nitrogen vapour phase: 5--8 years
                11% DMSO                                                    Piperacillin: 50 ug/mL\                                                                                                                        
                                                                            Amikacin: 25 ug/mL\                                                                                                                            
                                                                            Amphotericin B: 2.5 ug/mL                                                                                                                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Types and concentrations of antibiotics used for decontamination of allografts.

  Antibiotics/antifungals           Concentration/mL   Number of HVBs
  --------------------------------- ------------------ ----------------
  Vancomycin/vancocin               50--500 ug         15
  Gentamicin/garamycin              18--4000 ug        10
  Cefoxitin/cefotaxime/cefuroxime   240--1000 ug       6
  Amphotericin B                    2.5--50 ug         5
  Lincomycin                        120 ug--300 mg     3
  Penicillin/benzylpenicillin       30--50 IU          3
  Amikacin                          25--100 ug         3
  Polymyxin B                       200--1000 ug       3
  Piperacillin                      50--500 ug         2
  Colistin                          200 ug/1000 IU     2
  Streptomycin                      50 ug              2
  Tobramycin                        50 ug              1
  Cotrimoxazole                     50 ug              1
  Fluconazole                       500 mg             1
  Flucloxacillin                    200 ug             1
  Fungizone                         250 ug             1
  Fungoral                          100 ug             1
  Imipenem                          200 ug             1

###### 

Types of incubation media used for decontamination of allografts.

  Incubation media                                         Number of HVBs   \% of HVBs
  -------------------------------------------------------- ---------------- ------------
  Medium 199 (TC-199/M199)                                 11               46%
  Roswell Park Memorial Institute Media 1640 (RPMI-1640)   5                21%
  0.9% sodium chloride (normal saline)                     3                12.5%
  Dulbecco\'s Modified Eagle\'s Medium (DMEM)              2                8%
  Hanks Balanced Salt Solution (HBSS)                      2                8%
  Ringers lactate                                          1                4.5%

###### 

Incubation temperatures and durations used for decontamination of allografts.

  Incubation temperature (in °C)               Incubation time (in hours)   Number of HVBs   Number of HVBs   \% of HVBs
  -------------------------------------------- ---------------------------- ---------------- ---------------- ------------
  1--10 (cold temperature, including at 4°C)   6--24                        1                16               67%
  12--18                                       2                                                              
  18--26                                       12\*                                                           
  48                                           1                                                              
  21 (ambient temperature)                     18--26                       2                2                8.3%
  33--38 (physiological temperature)           6--12                        4\*              7                29%
  18--26                                       3                                                              

\*Refers to a HVB which decontaminates allografts at either 37°C for 6--8 hours or 4°C for 18--24 hours.

###### 

Summary of heart valve outcomes for HVBs in Europe.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bank   Number of donors/number of grafts processed annually (Average)   Proportion of products meeting release criteria   Reasons for product failure                                    Proportion of released products implanted                 Reasons released products are not implanted
  ------ ---------------------------------------------------------------- ------------------------------------------------- -------------------------------------------------------------- --------------------------------------------------------- -----------------------------------------------------------
  E1     45 donors\                                                       \~79%                                             \(1\) Abnormal morphology of graft\                            99.5%                                                     Decision during surgery
         75 valves                                                                                                          (2) Positive microbiological results of graft\                                                                           
                                                                                                                            (3) Positive serology results of donor                                                                                   

                                                                                                                                                                                                                                                     

  E2     25 donors\                                                       \~70%                                             \(1\) Failure in valve competency\                             95%                                                       Decision during surgery
         40 valves                                                                                                          (2) Positive microbiological results of graft\                                                                           
                                                                                                                            (3) Technical issues                                                                                                     

                                                                                                                                                                                                                                                     

  E3     97 grafts                                                        \~50%                                             Positive microbiological results                               95%                                                       \(1\) Size demands for valves\
                                                                                                                                                                                                                                                     (2) Low demand for type of valve

                                                                                                                                                                                                                                                     

  E4     72 donors\                                                       90%                                               \(1\) Failure in valve competency (primarily aortic valves)\   98%                                                       Decision during surgery, cancellation of surgery
         80 valves\                                                                                                         (2) Positive microbiological results of graft                                                                            
         130 patches                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                     

  E5     4 donors\                                                        \~69%                                             \(1\) Positive microbiological results of graft\               100%                                                      NA
         8 valves                                                                                                           (2) Positive serology results of donor                                                                                   

                                                                                                                                                                                                                                                     

  E6     35 donors\                                                       \~70%                                             Positive microbiological results of graft                      95%                                                       Low demand for aortic valves
         30 valves                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                     

  E7     20--30 donors\                                                   \~90%                                             \(1\) Positive microbiological results of graft\               60%                                                       Size demand for valves---a congenital cardiac centre only
         50 valves                                                                                                          (2) Technical issues                                                                                                     

                                                                                                                                                                                                                                                     

  E8     40--50 donors\                                                   \~80%                                             Positive microbiological results of graft                      95%                                                       \(1\) Size demand for valves\
         80 valves                                                                                                                                                                                                                                   (2) Beyond maximum storage duration of patch graft

                                                                                                                                                                                                                                                     

  E9     300 donors\                                                      \~50%                                             \(1\) Abnormal morphology of graft\                            85% (100% for pulmonary valves and arterial allografts)   \(1\) Aortic valve size\
         400 valves                                                                                                         (2) Positive microbiological results of graft\                                                                           (2) Low demand for aortic valves\
                                                                                                                            (3) Technical issues                                                                                                     (3) Decision during surgery\
                                                                                                                                                                                                                                                     (4) Damage of graft during thawing

                                                                                                                                                                                                                                                     

  E10    100 donors\                                                      \~68%                                             Abnormal morphology of graft                                   65%                                                       Size demand for valves
         250 grafts                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                     

  E11    217 donors\                                                      \~78%                                             \(1\) Abnormal morphology of graft\                            84%                                                       \(1\) Size demand for valves\
         380 valves                                                                                                         (2) Positive microbiological results of graft                                                                            (2) Low demand for aortic valves
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary of heart valve outcomes for HVBs in North America.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bank   Number of donors/no. of grafts processed annually (Average)                                  Proportion of products meeting release criteria   Reasons for product failure                         Proportion of released products implanted        Reasons released products not implanted
  ------ -------------------------------------------------------------------------------------------- ------------------------------------------------- --------------------------------------------------- ------------------------------------------------ -----------------------------------------
  N2     55 donors\                                                                                   \~70%                                             \(1\) Abnormal morphology of graft\                 100% for pulmonary valves\                       Low demand for aortic valves
         70 valves                                                                                                                                      (2) Positive serology results of donor\             20% for aortic valves                            
                                                                                                                                                        (3) Positive microbiological results of graft\                                                       
                                                                                                                                                        (4) Donor related                                                                                    

                                                                                                                                                                                                                                                             

  N3     42 donors\                                                                                   \~78%                                             Positive microbiological results of graft           32% of grafts were confirmed to be implanted,\   Low demand for aortic valves
         68 grafts                                                                                                                                                                                          16.5% of grafts were exported                    

                                                                                                                                                                                                                                                             

  N4     2400 grafts                                                                                  \~60%                                             \(1\) Positive microbiological results of graft\    80%                                              \(1\) Size demand for valves\
                                                                                                                                                        (2) Quality/donor related                                                                            (2) Nonvalve grafts are not in demand

                                                                                                                                                                                                                                                             

  N5     3700 donors\                                                                                 \~39%                                             \(1\) Deferred due to size/type of graft\           99%                                              Beyond maximum storage duration
         8500 grafts (including valves, patches, descending thoracic aorta and pericardium patches)                                                     (2) Graft attribute/abnormal morphology of graft\                                                    
                                                                                                                                                        (3) Positive microbiological results of graft                                                        

                                                                                                                                                                                                                                                             

  N6     34 donors\                                                                                   No response provided                              53%                                                 \(1\) Intraoperative contamination of graft\     
         57 grafts (valves, conduits, and pulmonary hemiarteries)                                                                                                                                           (2) Incorrect size of graft\                     
                                                                                                                                                                                                            (3) Beyond maximum storage duration              
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Summary table of heart valve outcomes for HVBs in Australasia and South Africa.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bank   Number of donors/number of grafts processed annually (average)   Proportion of products meeting release criteria   Reasons for product failure                        Proportion of released products implanted   Reasons released products are not implanted
  ------ ---------------------------------------------------------------- ------------------------------------------------- -------------------------------------------------- ------------------------------------------- ---------------------------------------------
  A1     12 donors\                                                       \~75%                                             \(1\) Positive microbiological results of graft\   77%                                         \(1\) Size demand for aortic valves\
         16 valves                                                                                                          (2) Abnormal morphology of graft                                                               (2) Low demand for aortic valves

                                                                                                                                                                                                                           

  A2     27 donors\                                                       \~50%                                             \(1\) Positive microbiological results of graft\   90--100%                                    Size demand for aortic valves
         77 grafts                                                                                                          (2) Donor related (medical contradiction)                                                      

                                                                                                                                                                                                                           

  A3     80 donors\                                                       \~70%                                             \(1\) Positive microbiological results of graft\   100% for pulmonary valves;\                 \(1\) Size demand for aortic valves\
         232 grafts\                                                                                                        (2) Positive serology results of donor             majority for aortic valves;\                (2) Beyond maximum storage duration
         (118 valves and 114 patches)                                                                                                                                          100% for patches                            

                                                                                                                                                                                                                           

  A4     20 donors\                                                       \~83%                                             \(1\) Positive microbiological results of graft\   74%                                         Low demand for aortic valves
         36 valves                                                                                                          (2) Abnormal morphology                                                                        

                                                                                                                                                                                                                           

  A5     24 donors\                                                       90%                                               Positive microbiological results of graft          \~100%                                      \(1\) Quality of graft\
         34 valves                                                                                                                                                                                                         (2) Beyond maximum storage duration

                                                                                                                                                                                                                           

  A6     29 donors\                                                       \~71%                                             \(1\) Positive microbiological results of graft\   91%\                                        Nonvalve grafts are not in demand
         49 valves                                                                                                          (2) Abnormal morphology\                                                                       
                                                                                                                            (3) Failure in valve competency                                                                

                                                                                                                                                                                                                           

  A7     75 donors\                                                       \~61%                                             \(1\) Positive serology results of donor\          \~80%                                       Size demand for valves
         98 valves                                                                                                          (2) Positive microbiological results of graft\                                                 
                                                                                                                            (3) Abnormal morphology of graft                                                               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Number of donors processed by HVBs, according to geographical region.

  Number of donors   Europe   North America   Australasia and South Africa   Total
  ------------------ -------- --------------- ------------------------------ -------
  \<50               7        2               5                              14
  51--100            2        1               2                              5
  101--1000          2        0               0                              2
  \>1000             0        2               0                              2

###### 

Reasons for product failure and why released products were not implanted.

  Reasons for product failure                  Number of HVBs   Reasons why released products were not implanted   Number of HVBs
  -------------------------------------------- ---------------- -------------------------------------------------- ----------------
  During evaluation of tissue and processing                    Uncontrollable factors                              
   Abnormal morphology                         10                Size demands for valves                           11
   Failure in valve competency                 3                 Aortic valve/nonvalve products not in demand      10
   Technical issues                            3                 Beyond maximum storage duration                   5
   Deferred due to size/type of graft          1                 Decision during surgery                           4
                                                                                                                   
  After tissue processing                                       Factors that can be improved on                     
   Positive microbiological results of graft   21                Damage of graft during thawing                    1
   Positive serology results of donor          5                 Intraoperative contamination of graft             1
   Quality/donor related                       3                 Incorrect size of graft                           1
   Quality of graft                            1                                                                   

[^1]: Academic Editor: F. H. J. Claas
